Evidence map›Paper›PMID 41120594›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

Preclinical evaluation and first-in-human study of

Xinlin Wang, Ming Wang, Yimin Chen, Ruotong Jian, Haonan Yu, Xiaojun Zhang, Jinming Zhang, Shaobo Yao, Jin Du, Mengchao Cui

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06690970 (Prostate Specific Membrane Antigen PET/CT Imaging in PSMA-Related Disease Patients), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06690970 recruitingnot on this map

Prostate Specific Membrane Antigen PET/CT Imaging in PSMA-Related Disease Patients

Typeobservational_patient_registrySponsorTianjin Medical UniversityRan2020 to 2027Enrolled500ConditionsPSMA-related Disease, Prostate Cancer, Positron Emission Tomography, MetastasisArms68Ga/18F-PSMA/PSFA
3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Dual-Target Nectin-4/FAP Heterobivalent ProbeAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xinlin Wang *Key Laboratory of Radiopharmaceuticals, Ministry of Education, Beijing Normal University, Beijing, 100875, China.
Ming Wang *Department of PET/CT Diagnostic, Tianjin Medical University General Hospital, Tianjin, 300052, China.
Yimin ChenKey Laboratory of Radiopharmaceuticals, Ministry of Education, Beijing Normal University, Beijing, 100875, China.
Ruotong JianKey Laboratory of Radiopharmaceuticals, Ministry of Education, Beijing Normal University, Beijing, 100875, China.
Haonan YuDepartment of PET/CT Diagnostic, Tianjin Medical University General Hospital, Tianjin, 300052, China.
Xiaojun ZhangDepartment of Nuclear Medicine, Chinese PLA General Hospital, Beijing, 100853, China.
Jinming ZhangDepartment of Nuclear Medicine, Chinese PLA General Hospital, Beijing, 100853, China.
Shaobo YaoDepartment of PET/CT Diagnostic, Tianjin Medical University General Hospital, Tianjin, 300052, China. yaoshaobo008@163.com.
Jin DuDepartment of Nuclear Technology and Application, China Institute of Atomic Energy, Beijing, 102413, China.
Mengchao CuiKey Laboratory of Radiopharmaceuticals, Ministry of Education, Beijing Normal University, Beijing, 100875, China. cmc@bnu.edu.cn.ORCID 0000-0002-3488-7864

Funding

Joint Funds for the Innovation of Science and Technology, Fujian Province 2024Y9138National Natural Science Foundation of China 22376016, 22022601National Natural Science Foundation of China 82171982Natural Science Foundation of Fujian Province 2023J06031
6 · The paper itself

Abstract

purposeProstate-specific membrane antigen (PSMA) expression may decrease during the progression of prostate cancer (PCa), compromising the efficacy of PSMA-targeted imaging. Fibroblast activation protein (FAP), a key component of the tumor microenvironment, offers a complementary target. This study aimed to develop and evaluate PSMA/FAP bispecific tracers with a biphenyl scaffold for improved PET detection outcomes of PCa.

methodsThe binding affinities of precursors and their corresponding non-radioactive standards were assessed using recombinant PSMA and FAP proteins. PET/CT imaging was performed in 22Rv1 (PSMA-positive) and U87MG (FAP-positive) xenograft models. Clinical evaluation of [

resultsAll precursors and their corresponding non-radioactive standards exhibited high affinity for both PSMA (K

conclusionsThe biphenyl-based bispecific tracers developed in this study achieved high tumor affinity, prolonged retention, and notably reduced renal uptake in mouse models. [

trial registrationClinical trial registry NCT06690970, Registered 14 Nov 2024.

Indexed as

Antigens, SurfaceFluorine RadioisotopesGlutamate Carboxypeptidase IIMembrane ProteinsPositron Emission Tomography Computed TomographyProstatic NeoplasmsSerine EndopeptidasesAnimalsCell Line, TumorEndopeptidasesGallium RadioisotopesHumansMaleMiceRadioactive TracersTissue DistributionAntigens, SurfaceEndopeptidasesFluorine-18Fluorine RadioisotopesFOLH1 protein, humanGallium RadioisotopesGlutamate Carboxypeptidase IIMembrane ProteinsRadioactive TracersSerine EndopeptidasesBispecific tracerFibroblast activation proteinFirst-in-humanPETProstate-specific membrane antigen

Identifiers

PMID41120594

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.